T790M, also known as Thr790Met, is a gatekeeper mutation of the epidermal growth factor receptor (EGFR). The mutation substitutes a threonine (T) with a methionine (M) at position …

The T790M mutation is most commonly found in cases of non-small-cell lung cancer (NSCLC) carrying a TKI-sensitive EGFR mutation (most frequently an in-frame deletion in exon 19 or an …

Dec 2, 2010 · Subsequent studies found that a secondary mutation in the EGFR gene (T790M mutation) and amplification of the MET proto-oncogene could be the main resistance …

EGFR T790M is a predictive biomarker for use of osimertinib, afatinib, dacomitinib, erlotinib, gefitinib, capmatinib, cetuximab, crizotinib, and pembrolizumab in patients. Of the therapies …

The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it …

Several second-generation EGFR-TKIs are currently being developed to overcome the acquired resistance caused by the T790M mutation. MET (met proto-oncogene) amplification or …

The T790M mutation is present in about half of the lung cancer patients with acquired resistance, and reported to act by increasing the affinity of the receptor to adenosine triphosphate, relative …

Feb 16, 2017 · In this trial, we found that patients with T790M-positive advanced non–small-cell lung cancer who received osimertinib had better response rates and a longer duration of …

Jan 3, 2012 · T790M was an independent predictor of decreased progression-free survival (PFS) in patients with NSCLC who received TKI treatment (P < .05, multivariate Cox regression).

Nov 21, 2019 · Osimertinib is a third-generation, irreversible, oral EGFR-TKI that selectively inhibits both EGFR-TKI–sensitizing and EGFR p.Thr790Met (T790M) resistance mutations …